ISPOR - EE303 Estimating Recurrences Prevented and Costs Avoided with Atezolizumab in Early Non-Small Cell Lung Cancer in the United States

EE303 Estimating Recurrences Prevented and Costs Avoided with Atezolizumab in Early Non-Small Cell Lung Cancer in the United States

Abstract

Authors

Z Elsisi R Sharma N Smith S Ogale JS Lee

Full Text Cite This Article

Back to Volume 25, Supplemental Issue 7S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now